New drug duo aims to boost immune attack on tough cancers

NCT ID NCT05789069

Ongoing Disease control Sponsor: HiFiBiO Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests an experimental drug called HFB200603, either alone or with the immunotherapy tislelizumab, in 83 adults with advanced solid tumors (kidney, lung, melanoma, stomach, or colon cancer). The main goal is to find a safe dose and check for side effects. Researchers will also watch for signs that the tumors shrink or stop growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HFB200603 (an experimental antibody) and tislelizumab (an approved immunotherapy)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced cancers like kidney, lung, or melanoma that have stopped responding to other therapies.
What could go wrong: This is a very early (Phase 1) trial with only 83 participants, so the main goal is safety, not effectiveness. The drug may not shrink tumors or could cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm gastric cancer gastric neoplasm melanoma non-small cell lung carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER GASTRIC CANCER MELANOMA NON-SMALL CELL LUNG CANCER RENAL CELL CARCINOMA

Contacts and locations

Locations

Centro Ricerche Cliniche di Verona s.r.l.

Verona, 37134, Italy
Clinica Universidad de Navarra - Madrid

Madrid, 28027, Spain
Clinica Universidad de Navarra - Pamplona

Pamplona, 31008, Spain
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Hospital Clinico Universitario de Valencia

Valencia, 46010, Spain
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

Naples, 80131, Italy
New Experimental Therapeutics of Virginia - NEXT Oncology

Fairfax, Virginia, 22031, United States
South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC

Madrid, 28050, Spain
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz

Madrid, 28040, Spain
UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

Rome, 00168, Italy
USC Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.